Organogenesis (ORGO) Competitors

Organogenesis (NASDAQ:ORGO) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Does the media prefer ORGO or EVO?

In the previous week, Evotec had 2 more articles in the media than Organogenesis. MarketBeat recorded 6 mentions for Evotec and 4 mentions for Organogenesis. Evotec's average media sentiment score of 1.23 beat Organogenesis' score of 1.10 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ORGO or EVO more profitable?

Evotec has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Evotec's return on equity of 0.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-1.62%	-2.69%	-1.63%
Evotec	N/A	N/A	N/A

Do analysts rate ORGO or EVO?

Organogenesis currently has a consensus target price of $5.50, indicating a potential upside of 78.57%. Evotec has a consensus target price of $5.93, indicating a potential upside of 46.14%. Given Organogenesis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Organogenesis is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Evotec	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Does the MarketBeat Community favor ORGO or EVO?

Organogenesis received 91 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 65.99% of users gave Organogenesis an outperform vote while only 50.00% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%
Evotec	Outperform Votes 6 50.00%	Underperform Votes 6 50.00%

Which has higher valuation & earnings, ORGO or EVO?

Organogenesis has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$458.76M	0.85	$4.95M	-$0.17	-18.12
Evotec	$788.22M	1.83	-$90.82M	N/A	N/A

Which has more risk & volatility, ORGO or EVO?

Organogenesis has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in ORGO or EVO?

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Organogenesis beats Evotec on 8 of the 15 factors compared between the two stocks.